Lilly Jumps to $1,500 as McDonald's Gets a Rare Sell

Analysts turned bullish on pharma and bearish on fast food in Monday's session.

Eli Lilly received the biggest target price hike of the day. JP Morgan's Chris Schott raised his target from $1,400 to $1,500, reiterating Buy. Lilly's market cap sits at over $1 trillion. Short interest is a mere 0.8% of free float — bears are scarce.

UBS also moved on Vertex Pharmaceuticals. Analyst Michael Yee lifted his price target from $585 to $615, keeping a Buy rating. Vertex carries a $133 billion market cap and just 1.9% SI % FF. Both pharma names are seeing rising conviction from Wall Street.

The day's sharpest call came on McDonald's. Melius Research's Jacob Aiken Phillips slapped a Sell on the fast-food giant with a target of just $230, down from $250. That's a significant cut. McDonald's commands a $167 billion market cap. Short interest sits at 1.7% of free float — still low, but bears may take note.

In tech, Lumentum Holdings saw a target price upgrade from the consensus. The photonics firm's average target rose to $1,157. Short interest stands at 8.1% of free float. Keefe, Bruyette & Woods also initiated Coinbase with a Buy at $237, adding fresh crypto optimism heading into quarter-end.